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WHAT IS ALREADY KNOWN ON THIS
SUBJECT
• Numerous previous case reports have
suggested that lupus can be induced by a
range of prescription medications.
• Analytical studies quantifying risk of
drug-induced lupus are lacking.
WHAT THIS STUDY ADDS
• This was the first large study to quantify risk
of lupus associated with carbamazepine,
hydralazine, and other prescription
medicines suspected of inducing the
disease.
• We confirmed some, but not all, associations
that have been hypothesized in case
reports.
• This study provides evidence that increased
risks may be causal given the lack of an
increased risk observed with deliberately
selected ‘comparison’ drugs.
AIM
To investigate the association between risk of lupus and exposure to
selected drugs implicated in risk of lupus in a number of case reports.
METHODS
In this matched nested case-control study we utilized primary care data
from the UK General Practice Research Database recorded between 1987
and 2001. Cases with at least one medical code for systemic lupus
erythematosus or drug-induced lupus in their computerized records
were matched to controls without a medical code for lupus or any other
autoimmune disorder. Using conditional logistic regression we computed
odds ratios (OR) and 95% confidence intervals (CI) for risk of lupus
associated with exposure to selected drugs.
RESULTS
There were 875 incident cases, of which 12% (n = 107) had evidence of a
prescription for one or more of the suspected drugs, and 3632 matched
controls. For some drugs, prescriptions were too uncommon to be able to
estimate associated risk of lupus. Despite small numbers of exposed
patients and low statistical precision we observed an increased risk of
lupus for hydralazine (OR = 6.62, 95% CI 1.03, 42.74), minocycline (OR =
4.23, 95% CI 2.65, 6.75) and carbamazepine (OR = 1.88, 95% CI 1.09, 3.22).
There was some indication that the effect of carbamazepine was
restricted to women (P for interaction by gender = 0.047).
CONCLUSION
This study shows that even those drugs suggested by case reports as
causing lupus cannot all be clearly shown to be associated, even in a
very large population-based database. Our findings support causal
relationships for carbamazepine, minocycline and possibly hydralazine.
Overall, drugs do not seem to be a major cause of lupus.
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Introduction
A wide range of prescription drugs has been linked to the
induction of auto-antibodies and, to a lesser extent, clini-
cally apparent autoimmune disease. The most extensively
documented drug-induced autoimmune disease is drug-
induced lupus (DIL). Prescription drugs from several thera-
peutic classes have been reported to lead to lupus [1, 2].
Convincing evidence exists for procainamide and hydrala-
zine; 20% of procainamide users and 5 to 8% of hydralazine
users are said to develop clinically apparent lupus within 1
year of use [3]. However, the majority of evidence for drugs
and risk of lupus comes from case reports and case series,
not quantitative analytical studies [4].Risks associated with
exposure to these drugs have therefore been defined
based on the quantity of case reports published in the
literature, with risk levels divided into ‘high’, ‘medium’, ‘low’
and ‘very low’ [4]. ‘Very low’ may be based on a single (and
potentially false-positive) case report [3].
No clear diagnostic criteria exist for DIL [2]. Many case
reports describe symptom resolution upon withdrawal of
the suspected drug and occasionally re-challenge has
resulted in re-appearance of symptoms, supporting a
causal association between suspected drugs and risk of
lupus [2, 4]. Since the clinical manifestations of the drug-
induced and idiopathic forms of lupus overlap, and formal
classification criteria for drug-induced lupus do not exist,
distinguishing between the two entities would require
data regarding the resolution and non-recurrence of
symptoms following termination of treatment with the
suspected medication. Laboratory and animal studies
provide further evidence of causal associations between
drugs and lupus [5].
The UK based General Practice Research Database
(GPRD) is a large primary care database that is widely used
for pharmaco-epidemiological studies [6]. It contains infor-
mation on a representative sample of about 6% of the UK
population. Because of its size the GPRD is especially useful
for studying relatively uncommon diseases such as lupus.
Here we report the results of a large population-based
matched case-control study utilizing the GPRD to assess
and quantify whether selected prescription drugs, impli-
cated in risk of lupus, are associated with risk of disease.
Methods
The GPRD
In the UK, over 98% of the population is registered with the
National Health Service (NHS). NHS practices contributing
to the GPRD are broadly representative of all UK practices
in terms of age and sex distribution of patients, and geo-
graphical distribution and size of practices [7]. Data from
the GPRD contain patient demographics, clinical data with
codes for diagnoses and symptoms and corresponding
consultation dates (including outcomes of specialist refer-
rals and hospitalizations), prescription data with corre-
sponding dates, dosages and methods of administration
and limited laboratory data. GPRD data are entered by
practice staff. Prior to central collection in the database,
data are anonymized and their quality is checked. If certain
quality criteria are met a practice is said to be ‘up-to-
standard’ (UTS) [8]. Various independent studies have
reported high quality and completeness of GPRD morbid-
ity data [8]. For prescription data, high agreement with
national data from the prescription pricing authority has
been observed [9]. Drug prescriptions are generated by
computer, irrespective of UTS status of a practice. We
observed no missing or incomplete date values in combi-
nation with the prescription data for exposures of interest.
Because of the high quality and completeness of the pre-
scription data, we included prescriptions from outside the
UTS period in the analyses. This enabled us to investigate
exposures occurring over a longer time period than would
have otherwise been possible.
Study period and base population
The base population consisted of the cohort of all individu-
als who were registered during 1987 to December 2001,
with a practice that contributed UTS data to the GPRD.This
study was part of a larger study of individuals with and
without autoimmune diseases, who were selected from
this base population.
Identification of incident lupus cases
We captured all individuals with diagnostic codes for sys-
temic lupus erythematosus (SLE) (available on request)
which were compiled from a coding dictionary by four
investigators (ES, ST, LS, AH), and verified by a rheumatolo-
gist whose subspecialty is lupus (W.J. McCune). Codes for
cutaneous forms of lupus were not included, except for
subacute cutaneous lupus (SCLE) since a high proportion
of patients with SCLE develop SLE [10]. The GPRD medical
dictionary contains one code for drug-induced lupus,cases
of which were also included in our case population.
Patients with at least one occurrence of a lupus code in
their medical records were identified from the GPRD. The
earliest occurrence of a lupus code corresponded to a
patient’s diagnosis date.
Incident lupus cases with a diagnosis date during the
study period and at least 12 months after the start of the
UTS period were included. This 12-month period was
chosen based on a method developed by Lewis et al. [11]
and described in further detail for lupus by Somers et al.
[10]. Cases which had a diagnosis recorded within 12
months of the start of the UTS period, and those with a
missing calendar date corresponding to a lupus diagnostic
code could potentially have had the disease for some time
and had their diagnosis recorded retrospectively (i.e. be
prevalent cases). These cases were excluded from the
analyses because it would not have been possible to
ensure that drug exposures had taken place before lupus
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diagnosis. Cases with coexisting autoimmune conditions
were also excluded, consistent with criteria used for con-
trols (described below).
Controls
Control subjects had no medical code for any known
autoimmune disease, and were eligible if there was at least
1 year between patient registration and occurrence of the
index date (i.e. date of lupus diagnosis for the matched
case). Up to five controls were matched to each case based
on sex, age and practice. Controls had to be registered with
their practice at the calendar date on which the matched
case was diagnosed with lupus. If no suitable control of the
same age was available, the window for matching was
extended by 1 year increments up to a maximum age dif-
ference of 9 years. Controls not showing any activity in
medical, therapy or prevention records in the 3 years
before index date were assumed to be inactive and
excluded from further analyses.
Exposure definition
Drugs of interest, which have been hypothesized to induce
lupus, are listed in Table 1.We investigated drugs which are
thought to be associated with a low, moderate or high risk
of inducing lupus, based on the number of published case
reports [4]. Drugs with an assigned risk level of ‘very low’
were not included in this study to limit the number of
comparisons undertaken and because of the very weak
evidence for such associations. We included a selection of
drugs that are not known to be linked to risk of lupus to
investigate whether effects were specific to the drugs
hypothesized to be associated with risk of lupus and to
check whether associations were therapeutic class specific.
We chose the following frequently used drugs to ensure
sufficient statistical power: doxycycline (a tetracycline anti-
biotic, as is the lupus-inducing drug minocycline), salbuta-
mol (an asthma drug) and diazepam (an anxiolytic).We did
not investigate drugs which have been reported to exac-
erbate pre-existing lupus or to initiate flares [3], because
exacerbations of existing disease are difficult to assess reli-
ably using clinical data from the GPRD. Risk of lupus asso-
ciated with penicillamine and sulfasalazine could not be
investigated because cases and controls did not have any
autoimmune disease other than lupus, and were thus
unlikely to be exposed to these two drugs for the autoim-
mune disease rheumatoid arthritis. If a study subject
received a prescription for a lupus-inducing or ‘compari-
son’ drug 1 week or longer before diagnosis (index) date,
this subject was considered to be exposed. No maximum
time limit between prescription and diagnosis was set to
ensure that all potential exposures were included. For
drugs to which more than 10 cases and controls were
exposed, we grouped number of prescriptions (as a proxy
for cumulative dose) into tertiles (based on their distribu-
tion among controls) with non-exposed individuals
serving as the reference group. This method of categoriza-
tion ensured that each exposure group contained suffi-
cient cases and controls to carry out investigation of risk of
lupus with increasing cumulative dose.
Statistical analysis
Conditional logistic regression was performed to model
risk of lupus associated with drug exposures of interest.
odds ratios (ORs) and 95% confidence intervals (CIs) were
calculated using Stata Software (Version 9, StataCorp,
Texas). We investigated whether risk of lupus increased
with increasing number of prescriptions by means of a test
for trend based on number of prescriptions.Two additional
covariates were added to the model based on a priori con-
siderations: number of years of available prescription data
between registration with the GP practice and lupus diag-
nosis date (index date for the controls), were included
because a study subject with a longer time period of GPRD
data is more likely to receive a prescription for a drug of
Table 1
Drugs of interest implicated in risk of lupus, with their estimated risk levels. Reprinted from Toxicology, Volume 209 (Issue 2), Robert L. Rubin, Drug-induced
lupus, page 13, Copyright (2005), with permission from Elsevier
Drug name Indication Drug class Risk*
Procainamide Arrhythmias Anti-arrhythmic High
Hydralazine Hypertension Vasodilator High
Quinidine Drug for acute malaria and to treat arrhythmias Anti-arrhythmic Moderate
Isoniazid Anti-tuberculosis drug Hydrazide Low
Minocycline Bacterial infection; primarily used to treat acne Antibacterials for systemic use; tetracycline Low
Carbamazepine Epilepsy Anti-convulsant; carboxamide derivative Low
Acebutolol Hypertension, angina and arrhythmias Antihypertensive; beta-adrenoreceptor blocker Low
Captopril Hypertension Antihypertensive; angiotensin-converting enzyme (ACE) inhibitor Low
Methyldopa Hypertension Antihypertensive; centrally acting anti-adrenergic agent Low
Chlorpromazine Schizophrenia and other psychoses Psycholeptic; antipsychotic Low
Prophylthiouracil Hyperthyroidism Systemic hormonal preparations; thyroid therapy Low
*Due to a lack of analytical studies, risks are currently assigned based on number of case reports published in the literature [3].
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interest as well as more likely to be diagnosed with lupus.
Number of consultations in the year preceding diagnosis
date (index date for the controls), was included because a
subject with more consultations is more likely to receive a
prescription for any drug (including drugs potentially asso-
ciated with risk of lupus) and more likely to be diagnosed
with lupus.
A potentially effect-modifying role of sex and age at
diagnosis (index) date, factors on which cases and controls
were individually matched, was investigated by computing
stratum-specific ORs for men and women, and for younger
or older age at diagnosis as defined by the median age at
diagnosis. Interaction by sex or age was assessed by adding
an interaction term in the regression model. To identify
whether DIL can be distinguished from idiopathic lupus by
means of its age- and sex distribution, we compared age-
and sex distributions of exposed cases with those of unex-
posed cases. For age, Wilcoxon rank-sum tests were per-
formed to compare median age in exposed vs. unexposed
cases. A chi-squared test (or Fisher’s exact for expected
values <5) was performed to investigate if the male : female
ratios differed between exposed and unexposed cases.
A Scientific and Ethical Advisory Group (SEAG) reviews
all study proposals wishing to utilize GPRD data. We
obtained ethics approval from SEAG and from the ethics
committee of the London School of Hygiene and Tropical
Medicine for this study.
Results
A total of 1375 incident cases of lupus were identified from
the GPRD, of whom 875 had no co-morbid autoimmune
disease and at least one available matched control, with
3632 matched controls in total (Table 2). 82.8% of the cases
were female. Median age at lupus diagnosis was 44.7 years
(SD 15.1); male cases were on average 7.4 years older than
females at diagnosis (median age 50.7 vs. 43.2 years, Wil-
coxon P < 0.0001).The observation period from study entry
to index date was longer for cases than controls (Table 2),
the mean for cases being 5.5 years and for controls being
4.9 years. Cases contacted their general practitioners more
frequently in the year prior to the index date, with a
median of 30 consultations (interquartile range (IQR)
16–53), compared with a median of 13 (IQR 5–28) consul-
tations among controls.
Crude and adjusted ORs for the association between
risk of lupus and selected drugs are shown in Table 3. None
of the prescription dates for any of the drugs of interest
had a missing value. No cases and controls were exposed
to procainamide, propylthiouracil or acebutolol andthere-
fore risk associated with these drugs could not be esti-
mated. Only cases were exposed to isoniazid. Very few
subjects were exposed to a further five drugs of interest,
resulting in wide confidence intervals (e.g. OR hydralazine
6.62, 95% CI 1.03, 42.7). For three drugs of interest more
than 10 cases and controls were exposed. Large numbers
of both cases and controls were exposed to the ‘compari-
son’ drugs.
The crude ORs for all drugs suspected of inducing lupus
were greater than 2.0 and statistically significant apart
from quinidine (3.94, 95% CI 0.55, 28.17) and methyldopa
(1.39, 95% CI 0.29, 6.70). Adjustment for confounders gen-
erally reduced the ORs but a more than four-fold increased
risk remained or hydralazine and minocycline and a statis-
tically significantly increased risk for carbamazepine.
In general,crude ORs for the‘comparison’drugs showed
an increased risk of lupus of less than 2.0. After adjustment
for confounding factors, including use of lupus-inducing
drugs, these associations were no longer apparent.
Table 2
Demographic characteristics and univariable odds ratios (ORs) with 95% confidence intervals (CIs) for the association between selected variables and
risk of lupus
Study subjects (%)
OR* (95% CI)Case (n = 875) Control (n = 3632)
Sex† Female 721 (82.4%) 3012 (82.9%)
Age at diagnosis (years)† Age (SD) 45.4 (15.1) 45.3 (15.1)
Range 4.5–85.5 4.5–88.4
Time in database (years)‡ 1–3 209 (23.9) 1112 (30.6) 1.00 (reference)
3–4.5 165 (18.9) 770 (21.2) 1.37 (1.03, 1.83)
4.5–7 246 (28.1) 950 (26.2) 2.43 (1.79, 3.30)
>7 255 (29.1) 800 (22.0) 4.27 (3.03, 6.02)
P < 0.001
Consultation rate§ 0–6 55 (6.29) 1060 (29.19) 1.00 (reference)
7–12 105 (12.00) 672 (18.50) 4.27 (2.95, 6.18)
13–24 194 (22.17) 826 (22.74) 8.51 (5.95, 12.2)
>24 521 (59.54) 1074 (29.57) 28.2 (19.4, 40.8)
P < 0.001
*Univariable odds ratio for risk of lupus. †Variable used to match cases and controls, therefore univariable OR is not reported. ‡Time (in years) in database before diagnosis. §Number
of consultations per year in the year preceding diagnosis date (index date for the controls).
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Gender-specific estimates are shown in Table 4. Very
few men were diagnosed with lupus as well as exposed to
a suspected drug.However, some evidence for effect modi-
fication by sex was seen for carbamazepine; only women
appeared to have an increased risk (P for interaction 0.047).
The male : female ratio for chlorpromazine-exposed cases
was significantly different from the ratio among unex-
posed cases (ratio exposed 1:0.77, ratio unexposed 1:4.7,
Fisher’s exact P = 0.021), suggesting that men are propor-
tionately more affected with chlorpromazine-induced
lupus than women, in contrast to idiopathic lupus. There
was no clear evidence of effect modification by sex or dif-
fering male : female ratios by exposure for any of the ‘com-
parison’ drugs. Stratum-specific estimates for younger and
older age at diagnosis could not be obtained for drugs
where no cases or controls were exposed (mostly among
Table 3




Unadjusted OR* (95% CI) Adjusted OR*†‡ (95% CI)Case (n = 875) Control (n = 3632)
Drugs suspected of inducing lupus§
Hydralazine 4 2 8.91 (1.62, 48.94) 6.62 (1.03, 42.74)
Minocycline 50 49 4.35 (2.90, 6.52) 4.23 (2.65, 6.75)
Carbamazepine 28 49 2.39 (1.48, 3.85) 1.88 (1.09, 3.22)
Quinidine 2 2 3.94 (0.55, 28.17) 1.41 (0.17, 11.95)
Methyldopa 2 7 1.39 (0.29, 6.70) 1.40 (0.28, 7.11)
Captopril 11 24 1.97 (0.95, 4.09) 1.30 (0.57, 2.96)
Chlorpromazine 7 16 1.95 (0.78, 4.87) 0.86 (0.32, 2.33)
Procainamide 0 0 – –
Propylthiouracil 0 0 – –
Acebutolol 0 0 – –
Isoniazid 3 0 – –
‘Comparison’ drugs not suspected of inducing lupus
Doxycycline 123 299 2.05 (1.61, 2.61) 1.21 (0.92, 1.59)
Diazepam 86 228 1.66 (1.26, 2.18) 0.92 (0.68, 1.26)
Salbutamol 135 411 1.44 (1.16, 1.79) 0.96 (0.76, 1.22)
*Reference category is the unexposed group for each drug. †ORs adjusted for time (in years) in database before diagnosis, and number of consultations in the year preceding
diagnosis or index date. ‡Control drugs additionally adjusted for exposure to lupus-inducing drug. §Drugs are reported to have high, moderate or low risk, based on number of
case reports published in the literature [3].
Table 4
Sex-specific adjusted odds ratios (ORs) and 95% confidence intervals (CIs) for the association between lupus and exposure to selected drugs before

















Drugs suspected of inducing lupus§
Hydralazine 2 1 2.87 (0.26, 31.71) 2 1 13.1 (1.04, 166) 0.387
Minocycline 45 44 4.29 (2.61, 7.06) 5 5 4.47 (1.08, 18.58) 0.885
Carbamazepine 25 39 2.47 (1.37, 4.48) 3 10 0.60 (0.15, 2.38) 0.047
Quinidine 2 2 1.36 (0.16, 11.65) 0 0 – –
Methyldopa 2 7 1.43 (0.28, 7.26) 0 0 – –
Captopril 9 16 1.84 (0.71, 4.76) 2 8 0.53 (0.09, 3.21) 0.203
Chlorpromazine 3 12 0.51 (0.12, 2.15) 4 4 1.75 (0.40, 7.69) 0.301
‘Comparison’ drugs not suspected of inducing lupus
Doxycycline 110 275 1.17 (0.88, 1.56) 13 24 1.62 (0.66, 3.97) 0.608
Diazepam 73 203 0.87 (0.62, 1.21) 13 25 1.34 (0.59, 3.03) 0.437
Salbutamol 105 335 0.88 (0.68, 1.15) 30 76 1.29 (0.75, 2.22) 0.199
*Reference category is the unexposed group for each drug. †ORs adjusted for time (in years) in database before diagnosis, and number of consultations in the year preceding
diagnosis or index date. ‡Control drugs additionally adjusted for exposure to lupus-inducing drug. §Drugs are reported to have high, moderate or low risk, based on number of
case reports published in the literature [3].
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those aged younger than 45 years). Risks which could be
estimated were similar to the overall estimates (data not
shown). However, risk of minocycline-induced lupus
appeared to be lower at younger age (<45 years; 34 cases
and 41 controls exposed; OR = 3.38 (95% CI 1.94, 5.90))
compared with older age (45 years, 16 cases and 8 con-
trols exposed, OR = 7.93, 95% CI 3.12, 20.17).This difference
was not statistically significant (P for interaction 0.117).
Comparing median age of exposed vs. unexposed cases
revealed that cases with a history of exposure to minocy-
cline were on average 8.5 years younger than minocycline-
unexposed cases (Wilcoxon test P = 0.004). Exposed cases
were substantially older than unexposed cases for hydrala-
zine (24.6 years older, P = 0.009),quinidine (17.8 years older,
P = 0.094) and captopril (12.1 years older, P = 0.004).
For minocycline there was a clear trend of increasing
risk of DIL with increasing number of prescriptions
(adjusted OR per 10 prescriptions 3.10, 95% CI 2.10, 4.55, P
for trend < 0.001) (Table 5) and some evidence was found
for carbamazepine (adjusted OR per 10 prescriptions 1.27,
95% CI 1.04, 1.57, P for trend = 0.011). No clear associations
were observed for chlorpromazine and captopril. Among
the ‘comparison’ drugs, only doxycycline showed weak evi-
dence of a trend of increasing risk with increasing number
of prescription (P = 0.054), however this could not be veri-
fied with the adjusted OR per 10 prescriptions 1.15, 95% CI
0.90, 1.49.
Current use of minocycline or chlorpromazine was
associated with a four-fold increased risk of lupus (OR =
4.05, 95% CI 1.04, 15.76) and two-fold increased risk (OR =
2.27, 95% CI 0.27, 19.02), respectively. Increasing time since
cessation of drug use was associated with a decreased risk
of lupus for minocycline and chlorpromazine, which was
confirmed by a test for trend (minocycline P = 0.009, chlo-
rpromazine P = 0.031). Time since cessation of use of car-
bamazepine, captopril and all of the ‘comparison’ drugs
Table 5








OR†‡ (95% CI)Case (n = 875)
Control
(n = 3632)
Drugs suspected of inducing lupus§
Minocycline Unexposed 825 3583 1.00 (Reference) 1.00 (Reference)
1 17 22 3.43 (1.81, 6.51) 3.03 (1.49, 6.17)
2–3 13 12 4.31 (1.94, 9.60) 6.10 (2.20, 16.93)
4 20 15 5.67 (2.88, 11.14) 5.00 (2.37, 10.51)
P < 0.001 P < 0.001
Carbamazepine Unexposed 847 3583 1.00 (Reference) 1.00 (Reference)
1 9 16 2.39 (1.05, 5.45) 1.55 (0.62, 3.84)
2–6 4 17 0.96 (0.32, 2.89) 0.94 (0.27, 3.25)
7 15 16 3.83 (1.88, 7.80) 3.04 (1.34, 6.85)
P < 0.001 P = 0.011
Captopril Unexposed 864 3608 1.00 (Reference) 1.00 (Reference)
1–13 Rx 8 13 2.58 (1.06, 6.26) 2.13 (0.79, 5.73)
14 Rx 3 11 1.20 (0.32, 4.40) 0.56 (0.14, 2.29)
P = 0.180 P = 0.970
Chlorpromazine Unexposed 868 3616 1.00 (Reference) 1.00 (Reference)
1 Rx 4 11 1.60 (0.49, 5.27) 0.63 (0.17, 2.26)
2 Rx 3 5 2.65 (0.63, 11.2) 1.48 (0.29, 7.42)
P = 0.124 P = 0.987
‘Comparison’ drugs not suspected of inducing lupus
Doxycycline Unexposed 752 3333 1.00 (Reference) 1.00 (Reference)
1 Rx 69 208 1.64 (1.22, 2.20) 1.05 (0.75, 1.45)
2–3 Rx 43 71 3.30 (2.18, 4.99) 1.60 (1.01, 2.54)
4 Rx 11 20 2.80 (1.29, 6.05) 1.56 (0.68, 3.55)
P < 0.001 P = 0.054
Diazepam Unexposed 789 3404 1.00 (Reference) 1.00 (Reference)
1 50 118 1.85 (1.30, 2.62 1.10 (0.74, 1.63)
2–3 19 53 1.64 (0.96, 2.81) 0.79 (0.44, 1.42)
4 17 57 1.28 (0.74, 2.23) 0.73 (0.40, 1.33)
P = 0.009 P = 0.297
Salbutamol unexposed 740 3221 1.00 (Reference) 1.00 (Reference)
1 Rx 40 161 1.08 (0.75, 1.56) 0.85 (0.57, 1.26)
2–6 Rx 52 126 1.85 (1.31, 2.59) 1.23 (0.84, 1.79)
7 Rx 43 124 1.49 (1.04, 2.15) 0.83 (0.55, 1.25)
P < 0.001 P = 0.744
*Categorization number of prescriptions based on distribution in controls. †Adjusted for years in database before diagnosis and number of consultations in year prior diagnosis.
‡Drugs not known to induce lupus additionally adjusted for use of lupus drug yes/no. §Drugs are reported to have high, moderate or low risk, based on number of case reports
published in the literature [3]. Rx prescription.
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was not clearly associated with risk of lupus (data not
shown).
Discussion
In this large matched case-control study we found an
increased risk of lupus among individuals who were
exposed to hydralazine, minocycline and carbamazepine.
For the latter two drugs, risk increased with increasing
cumulative dose. Although the number of individuals
exposed to carbamazepine was small, the association
appeared stronger among women than men.
To our knowledge this was the first large study to quan-
tify risk of lupus associated with carbamazepine, hydrala-
zine, and other prescription medicines suspected of
inducing the disease.We confirmed some, but not all, asso-
ciations that have been hypothesized in case reports [3].
Given the relatively low incidence of lupus [10] and infre-
quent use of many of the suspected drugs, the number of
patients who are newly diagnosed with a drug-induced
form of lupus is likely to be low.Twelve per cent of the 875
incident lupus cases in this study had evidence of a pre-
scription for one or more of the suspected drugs, leaving
the vast majority of lupus cases with unexplained aetiol-
ogy of their disease.
One previous GPRD study investigating minocycline-
induced lupus among acne patients [12] identified a clear
association between exposure to minocycline and risk of
lupus among 29 cases with lupus-like syndrome who were
aged 15–29 years. Margolis et al. [13] also investigated risk
of lupus among acne patients utilizing a UK database (The
Health Improvement Network) similar to the GPRD. In their
study, an association with risk of lupus was found for
minocycline but not for other tetracyclines, among acne
patients aged 15–35 years.
In our study, the power to detect moderately increased
risks or to perform relevant subgroup analyses was limited,
even in the largest population-based data set available to
date.For some drugs,prescriptions were too uncommon to
be able to estimate associated risk of lupus. Despite small
numbers of exposed patients and low statistical precision
of some of our risk estimates, the magnitude of the risks
observed for hydralazine and minocycline as well as the
observed increased risk with increasing number of pre-
scriptions for minocycline and carbamazepine provide evi-
dence to support a causal relationship.
Evidence for a causal association between drugs and
risk of lupus has previously been demonstrated by disap-
pearance of symptoms after withdrawal of a suspected
drug [14]. In addition, re-challenge with the suspected
drug has been reported to result in re-appearance of
symptoms [15, 16]. Neither formal criteria nor International
Classification of Diseases (ICD) codes exist for the classifi-
cation and coding of DIL.Thus the distinction between DIL
and idiopathic SLE relies on the resolution and non-
recurrence of symptoms following medication termina-
tion. Because the GPRD does not contain codes for
recovery from disease we were not able to investigate
directly causality or distinguish between DIL and SLE cases
in this manner. We were also not able to distinguish SLE
from DIL based on the computerized medical codes
recorded by the GP. Of the 107 cases with evidence of
exposure to a lupus-inducing drug before their diagnosis,
only one had a code with a qualifier for drug-induced. All
other patients had a recorded diagnosis of SLE. It has been
hypothesized that DIL patients are generally older and
more likely to be male than cases with idiopathic SLE [2].
We found some evidence for a male preponderance of
chlorpromazine-induced lupus, but not for other drugs.
The older median ages observed among DIL cases
exposed to hydralazine, quinidine and captopril compared
with unexposed SLE cases are as expected since these
drugs are indicated for conditions generally diagnosed at
older age (Table 1).
In order to assess whether an association is causal, it is
important to ensure that drug exposure took place prior to
onset of disease. We defined lupus diagnosis date as the
date on which the first medical code for lupus was
recorded in a patient’s medical file. Accurately assessing
the lupus diagnosis date based on computerized medical
information is a complex task, since the first occurrence of
a code for lupus may not necessarily reflect the date on
which symptoms of the disease first appeared. In theory, an
alternative approach may be to define the lupus diagnosis
date as the date on which the first prescription for a lupus-
specific treatment was issued, or on which symptoms first
became apparent. In practice this approach would also
result in inaccurate assessment of diagnosis dates since
many treatments and symptoms for lupus are non-specific
and seen in a wide range of other diseases.
When studying the association between exposures and
risk of disease, it is important to ensure only true cases are
included in the study. In clinical practice, the classification
of SLE is based on criteria formulated by the American
College of Rheumatology [17, 18]. Laboratory test results
for anti-nuclear antibody (ANA) or anti-DNA antibody posi-
tivity were not available for the majority of our cases and
we did not validate a diagnosis of SLE for each case indi-
vidually.We believe this did not result in incorrectly includ-
ing many non-SLE patients as cases in our study, since
incidence rates based on our data were consistent with
other published estimates [10]. Criteria for diagnosis of DIL
are less strict than those for diagnosis of idiopathic lupus
[3, 15].The set of diagnostic codes we included in our defi-
nition may have excluded codes that were preferred by
GPs to describe the symptoms of DIL.
Bias in recording exposure to suspected drugs was vir-
tually non-existent in our study, because all prescription
information was recorded in a prospective manner prior to
the diagnosis (index) date. A potential source of bias in this
study may have been protopathic bias, i.e. when early
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symptoms of a disease influence the likelihood of being
exposed to a certain drug [19]. For example, skin problems
which may have been an early presentation of the typical
butterfly-shaped rash seen in idiopathic lupus may have
been misdiagnosed as acne and treated with minocycline
or doxycycline. Protopathic bias is therefore a possible
explanation for the marginally increased point estimates
observed for doxycycline. For minocycline, however, the
strongly increased point estimates and confidence limits
cannot be fully explained by protopathic bias and suggest
a causal, drug-specific association with risk of lupus. Eth-
nicity is a known risk factor for lupus but little, if any, evi-
dence exists that the relevant drug prescribing patterns
are associated with ethnicity in a systematic way.Thus eth-
nicity is unlikely to be a strong confounding factor in our
study, as it would need to be associated with both drug
exposure and outcome.
Consultation behaviour was included as a confounding
factor in our models, even though one could argue it is on
the causal pathway between drug exposure and induction
of lupus. We believe it was appropriate to adjust for con-
sultation behaviour as after adjustment, the increased risk
of lupus disappeared for the‘comparison’drugs, but not for
the drugs thought to induce lupus. A GPRD-based study of
minocycline-induced lupus in a population of acne
patients reported an 8.5-fold increased risk of lupus for use
of minocycline at the time of lupus diagnosis [12]. Exclud-
ing past users of minocycline from our study results in a
similar unadjusted 8-fold increased risk. Adjustment for
confounders reduced this risk to 4, highlighting the poten-
tial influence of consultation behaviour and length of
therapy on risk estimates of lupus.
Numerous case reports have suggested that lupus can
be induced by a range of prescription medications but
these have not been investigated in sufficiently large
observational studies. The present study used the largest
population-based database available to date and still
lacked statistical power to reliably confirm or exclude an
effect for a number of the suspected drugs.We did observe
a substantially increased risk of lupus associated with
exposure to hydralazine and minocycline and moderately
increased risk for carbamazepine. These observed
increased risks may be causal given the lack of an
increased risk observed with deliberately selected ‘com-
parison’ drugs. Our results are based on a representative
sample of UK individuals, and as such these findings are
likely to be generalizable.
Although the majority of selected drugs investigated in
our study are not used commonly, a possible diagnosis of
lupus should always be considered given that potentially
serious symptoms of the drug-induced form are thought
to be reversible [2]. Recently, newer drugs such as anti-
tumour necrosis factor (TNF) inhibitors have also been
linked to induction of lupus [20]. These biologicals are not
routinely administered in primary care and were not
approved for widespread use in the UK during the study
period, so it was not be possible to quantify their risk of
inducing lupus in our study. However, in the current age of
computerized medical records it is possible that other (and
larger) sources will become available in the near future,
perhaps through pooling of national data and linkage of
several data sources [21]. Such large databases are needed
to evaluate signals of DIL and to assess causality of these
rare but serious events associated with uncommonly used
prescription medicines.
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